Ben van der Schaaf

Partner

United States

Life Sciences expert working with biopharmaceutical companies to solve their biggest challenges pragmatically

Education

Henley Management College
Business Design; Business & Enterprise Architecture
University of Maine - School of Business
Master of Business Administration
NIVRA-Nyenrode
NACII, Accountancy

Past Experience

PA Consulting Group
Management Consultant
The Tussauds Group
Director of Finance
Ernst & Young
Auditor

Ben is a Life Sciences partner based in Arthur D. Little’s New York office. He is a pharmaceutical expert who works closely with companies to help solve urgent operational issues; designs and implements transformation programs and has extensive experience supporting transactions – both divestment and integration, especially from the operational side. 

He is an experienced management consultant and program manager with an international background in finance and general management with 30+ years total experience of which the last 15 have been in the pharmaceutical industry.

Select project experiences include post-merger integration, complex program design and delivery, quality & compliance related programs, strategic sourcing & partnering, organizational analysis and design, commercialization, sales-force effectiveness and operations management. In addition, Ben is skilled in stakeholder management, change management and collaboration, and has broad international business experience. He operates and communicates comfortably across cultures, levels and functions.
Ben holds an MBA with an operations and finance concentration, and an undergraduate degree in accounting and auditing. He is fluent in Dutch and English.
 

Why patient centricity is key to long-term pharma company success
Why patient centricity is key to long-term pharma company success
Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs. Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.
From good to great: Enhancing innovation performance through effective management processes
From good to great: Enhancing innovation performance through effective management processes
COVID-19 – FOCUSING ATTENTION ON THE NEXT TRANSFORMATION IN HEALTHCARE
Essentially the pandemic has shown the strengths and weaknesses of the global healthcare sector – and the opportunities that exist for improvement and transformation. While demonstrating what can be achieved through global collaboration, COVID-19 has also shone a harsh light on the disparities in healthcare access between developed and developing countries.

Ben is a Life Sciences partner based in Arthur D. Little’s New York office. He is a pharmaceutical expert who works closely with companies to help solve urgent operational issues; designs and implements transformation programs and has extensive experience supporting transactions – both divestment and integration, especially from the operational side. 

He is an experienced management consultant and program manager with an international background in finance and general management with 30+ years total experience of which the last 15 have been in the pharmaceutical industry.

Select project experiences include post-merger integration, complex program design and delivery, quality & compliance related programs, strategic sourcing & partnering, organizational analysis and design, commercialization, sales-force effectiveness and operations management. In addition, Ben is skilled in stakeholder management, change management and collaboration, and has broad international business experience. He operates and communicates comfortably across cultures, levels and functions.
Ben holds an MBA with an operations and finance concentration, and an undergraduate degree in accounting and auditing. He is fluent in Dutch and English.
 

Why patient centricity is key to long-term pharma company success
Why patient centricity is key to long-term pharma company success
Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs. Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.
From good to great: Enhancing innovation performance through effective management processes
From good to great: Enhancing innovation performance through effective management processes
COVID-19 – FOCUSING ATTENTION ON THE NEXT TRANSFORMATION IN HEALTHCARE
Essentially the pandemic has shown the strengths and weaknesses of the global healthcare sector – and the opportunities that exist for improvement and transformation. While demonstrating what can be achieved through global collaboration, COVID-19 has also shone a harsh light on the disparities in healthcare access between developed and developing countries.

More About Ben
  • Henley Management College
    Business Design; Business & Enterprise Architecture
  • University of Maine - School of Business
    Master of Business Administration
  • NIVRA-Nyenrode
    NACII, Accountancy
  • PA Consulting Group
    Management Consultant
  • The Tussauds Group
    Director of Finance
  • Ernst & Young
    Auditor